Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,3584,380,39
Msft1,58
Nokia4,3894,48-0,27
IBM1,50
Mercedes-Benz Group AG50,1950,21-1,01
PFE0,24
04.07.2025 18:00:42
Indexy online
AD Index online
select
AD Index online
 

  • 03.07.2025 23:00:00
Amphastar Pharmactc (NASDAQ Cons)
Závěr k 3.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
23,20 -1,61 -0,38 221 782
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.07.2025
Popis společnosti
Obecné informace
Název společnostiAmphastar Pharmaceuticals Inc
TickerAMPH
Kmenové akcie:Ordinary Shares
RICAMPH.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 2 028
Akcie v oběhu k 01.05.2025 47 139 085
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice11570 6th St
MěstoRANCHO CUCAMONGA
PSČ91730
ZeměUnited States
Kontatní osobaDan Dischner
Funkce kontaktní osobyVice President - Corporate Communications
Telefon19 099 809 484
Fax13026555049
Kontatní telefon19 099 809 484

Business Summary: Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Amphastar Pharmaceuticals Inc revenues decreased 1% to $170.5M. Net income decreased 41% to $25.3M. Revenues reflect United States segment decrease of 4% to $162.6M, China segment decrease of 80% to $81K. Net income also reflects Other Nonoperating Income (Expense) decrease from $5.9M (income) to $2.2M (expense), Selling, distribution and marketing increase of 33% to $8.6M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 05.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Operating Officer, Chief ScientistZiping Luo7501.01.1996
President, Chief Executive Officer, Chief Scientific Officer, DirectorYongfeng Zhang7810.04.202001.01.1996
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, DWilliam Peters5704.08.2022
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals,Jacob Liawatidewi5104.08.2022
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar NanRong Zhou66